Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMIERE long-term safety registry in multiple sclerosis after cladribine trials
2009-017978-21Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cladribine in multiple sclerosis (MS), sponsored by Merck Serono. Primary endpoint: Cumulative incidence of serious adverse drug reactions. Started Nov 2010; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-017978-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017978-21.